P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES

• A. Broijl,
• N. van de Donk,
• F. Bosch,
• M. V. Mateos,
• P. Rodriguez-Otero,
• A. Tucci,
• P. Ghia,
• A. Adang,
• P. Parren,
• I. Tuinhof,
• S. Umarale,
• B. Winograd,
• H. van der Vliet,
• A. Kater

Affiliations

A. Broijl

1 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam

N. van de Donk

2 Department of Hematology, Cancer Care Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

F. Bosch

3 Department of Hematology, Hospital Vall d’Hebron, Barcelona

M. V. Mateos

4 Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca

P. Rodriguez-Otero

5 Department of Hematology, Clínica Universidad De Navarra, Pamplona, Spain

A. Tucci

6 Department of Hematology, ASST Spedali Civili di Brescia, Brescia

P. Ghia

7 Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

A. Adang

8 LAVA Therapeutics N.V., Utrecht, Netherlands

P. Parren

8 LAVA Therapeutics N.V., Utrecht, Netherlands

I. Tuinhof

8 LAVA Therapeutics N.V., Utrecht, Netherlands

S. Umarale

8 LAVA Therapeutics N.V., Utrecht, Netherlands

B. Winograd

8 LAVA Therapeutics N.V., Utrecht, Netherlands

H. van der Vliet

8 LAVA Therapeutics N.V., Utrecht, Netherlands

A. Kater

2 Department of Hematology, Cancer Care Amsterdam, Amsterdam UMC, Amsterdam, Netherlands